PeakForce Labs is a specialized research compound supplier built on a single principle: every claim we make about our compounds is verifiable, documented, and independently confirmed. Not because it is required — because it is the only way to serve researchers who cannot afford uncertainty.
PeakForce Labs was founded out of a recurring frustration within the research community: the gap between what compound suppliers claimed and what independent analysis actually confirmed. Researchers were spending significant time and resources validating material that should have arrived validated. We built PeakForce to close that gap permanently.
We are not a general-purpose chemical distributor that handles research compounds as one product category among many. Our entire operational model — from procurement of raw synthesis precursors to final batch release — is designed specifically for the demands of serious research environments. Every operational decision we make is filtered through a single question: does this make the researcher's work more reliable?
Our team combines backgrounds in analytical chemistry, biochemistry, regulatory documentation, and research logistics. This is not a company built around margins and catalog size. It is a company built around the conviction that the quality of research depends in part on the quality of its inputs, and that compound suppliers have an obligation to the integrity of the work they enable.
Today, PeakForce Labs serves independent researchers, academic institutions, and private research organizations across North America. We maintain a deliberately focused catalog — not because we cannot source more widely, but because depth of documentation and verification is incompatible with unlimited breadth at our scale. Every compound we stock is one we can fully stand behind with documentation we would stake our reputation on.
We publish all batch-level Certificates of Analysis publicly, without requiring account creation or purchase history. We believe transparency is not a feature to be unlocked — it is the baseline expectation of any serious supplier operating in this space.
Our mission is not defined by the compounds we supply. It is defined by the certainty researchers can attach to those compounds. We exist to remove a specific source of uncertainty from the research process.
Every compound in our catalog can be traced from its synthesis origin through every analytical checkpoint to its batch release date. We maintain complete chain-of-custody documentation that is available to researchers upon request. Traceability is not a compliance exercise for us — it is the foundation of reproducible science.
We do not test our own materials. Every analytical result attached to a PeakForce compound comes from laboratories with no financial relationship to our organization beyond the testing fee. We consider self-certification to be a fundamental conflict of interest, and we have built our entire documentation pipeline around third-party verification as the non-negotiable standard.
We publish full Certificates of Analysis for every batch of every compound we stock. These documents include raw analytical data, not just summary pass/fail statements. Researchers deserve access to the actual numbers — chromatography peak areas, mass spectra confirmation, endotoxin assay values — not just assurances that those numbers were reviewed by someone.
We treat our quality procedures as living documents. When analytical techniques improve, we adopt them. When a batch raises any question — even if it technically passes all required thresholds — we investigate before releasing. Our standard is not "did this batch pass?" It is "are we confident in this batch?" Those are different questions, and we answer the harder one.
Every operational decision at PeakForce — from how we format our COA documents to how we handle batch variation questions — is made with the working researcher in mind. We answer technical questions directly. We provide documentation in formats that integrate cleanly with laboratory information management systems. We do not hide behind disclaimers when a straightforward answer is available.
We stock a focused catalog of well-characterized compound categories where we can maintain our documentation standards without compromise. We will not expand our catalog faster than our quality infrastructure can support. This is a deliberate constraint, not a limitation — it is how we ensure that every compound we supply meets the same standard as every other compound we supply.
Quality assurance at PeakForce Labs is not a final inspection before shipment. It is an integrated process woven through every stage of how a compound moves from synthesis to researcher. Here is how that process works.
Before a synthesis partner or raw material supplier enters our supply chain, they undergo a rigorous qualification process. We review their quality management documentation, their analytical capabilities, and their track record with third-party audits. We do not work with suppliers who cannot provide this documentation. New supplier relationships begin with an extended evaluation period before any material from that source enters our active catalog.
Every shipment of raw material or synthesized compound is quarantined upon arrival and subjected to an initial identity and gross purity check before it is logged into our inventory system. Material that does not pass this initial inspection is returned or destroyed — it does not enter our facility's active storage under any circumstances. This creates a documented checkpoint that exists independently of the supplier's own quality records.
Following the initial inspection, each batch is sent to our network of independent accredited analytical laboratories. We use multiple laboratories, not a single preferred partner, to prevent any systematic bias from entering our results. Laboratories receive samples without knowledge of the supplier source. This blind-testing approach is designed to generate results that reflect actual material quality, not relationship dynamics.
Raw analytical data from independent laboratories is reviewed by our in-house analytical chemistry team. We do not rely solely on the laboratory's pass/fail determination. Our team reviews the underlying chromatography traces, spectral data, and assay values directly. Where any result falls outside expected ranges — even if technically within stated acceptance criteria — we flag it for additional investigation before proceeding.
Once all analytical results are reviewed and approved, our documentation team compiles the Certificate of Analysis for the batch. Our COA format is designed to provide researchers with all of the data they need to make an informed determination about the material's suitability for their specific application. We include raw data summaries, not just conclusions, and we provide reference ranges for all reported values.
Batch release requires a formal sign-off from both our analytical team and our quality assurance director. No batch enters active inventory based on a single reviewer's approval. This two-party authorization creates a documented accountability chain and ensures that the decision to release a batch for researcher use has been made with appropriate deliberation. Release authorization records are maintained as part of the batch's permanent documentation file.
Approved batches are stored under continuously monitored conditions appropriate to their specific stability requirements. Temperature and humidity logs are recorded at 15-minute intervals and reviewed weekly. Batches that experience any storage condition excursion — regardless of how brief — are flagged for re-testing before further distribution. Stability data informs storage condition assignments, and we err toward more conservative storage conditions where stability data shows any ambiguity.
Before dispatch, each order is checked against the batch record to confirm that the material being shipped corresponds to the documented, released batch. Packaging materials are selected for their stability properties, and cold-chain shipments use validated packaging configurations. The batch lot number included with each shipment allows researchers to locate the corresponding COA directly on our documentation portal without requiring any account login.
Our six-point testing protocol was designed in consultation with analytical chemists to address the most common and consequential failure modes in research compound supply. Each assay answers a specific question that matters to the reliability of downstream research.
HPLC analysis provides quantitative purity assessment by separating the compound from its impurities and measuring the relative area under each peak. We report purity as a percentage of the main compound peak area relative to total chromatographic area. Our minimum acceptance threshold is 99.0% — and we publish the actual numerical result, not just confirmation that the threshold was met. HPLC is run using validated methods appropriate to each compound class.
Mass spectrometry confirms the molecular identity of the compound by measuring the mass-to-charge ratio of ionized fragments. Identity confirmation via mass spectrometry is non-negotiable in our protocol — purity alone is insufficient if the compound's identity has not been independently verified. We use electrospray ionization (ESI-MS) as standard, with additional fragmentation pattern analysis where the compound structure warrants it.
Endotoxins — lipopolysaccharides from gram-negative bacterial cell walls — are a common contaminant in biologically-derived and synthesized compounds and can significantly confound research results, particularly in cell-based assays and in vivo models. We use the Limulus Amebocyte Lysate (LAL) assay to quantify endotoxin levels in every batch, and we publish the EU/mg result in our COA documentation.
The synthesis of research compounds involves organic solvents that must be removed before the final product is suitable for research use. Residual solvent testing using gas chromatography with headspace sampling quantifies trace solvent levels and confirms compliance with ICH Q3C residual solvent guidelines. Solvent profiles vary by synthesis method, and we test specifically for the solvents known to be present in each compound's synthesis pathway.
Trace metal contamination from synthesis equipment, catalysts, and reagents can introduce unpredictable variables into research results. We screen each batch for a standard panel of heavy metals including lead, mercury, arsenic, and cadmium using inductively coupled plasma mass spectrometry (ICP-MS). Results are reported against established reference limits, and we provide the actual quantitative values rather than simple pass/fail statements.
Water content in lyophilized and powdered compounds affects both the accuracy of gravimetric measurements and the long-term stability of the material. We use Karl Fischer titration to determine water content as a percentage of total mass, and we report this value in our COA. Researchers can use this figure to adjust their reconstitution calculations for higher-precision applications where the difference between 98% and 99% pure compound on a dry-weight basis is significant.
A Certificate of Analysis is only as useful as the information it contains. We have designed our COA format based on direct input from researchers about what documentation actually supports their work.
Each COA includes a unique batch identifier, synthesis date, testing date, and release date. This information allows researchers to identify exactly which batch of material was used in their work and to locate the corresponding documentation years later if reproducibility questions arise. We maintain COA archives indefinitely and do not remove historical batch documentation when batches are exhausted.
We include numerical values, not just pass/fail statements. Purity is reported as a percentage value, not simply as "meets specification." Endotoxin levels are reported in EU/mg. Water content is reported as a percentage. This approach allows researchers to assess whether the compound meets their specific requirements, which may be more or less stringent than our standard acceptance criteria depending on the application.
Every COA identifies the independent laboratory or laboratories that performed the analytical testing for that batch. We include laboratory accreditation information and, where available, direct links to the laboratory's accreditation certificate. Researchers who want to verify the testing laboratory's credentials independently can do so without any additional requests to our team.
For each test performed, our COA cites the analytical method used, including any relevant pharmacopoeial or industry standard references. Where proprietary methods are used by testing laboratories, we note this and provide the key method parameters. This citation practice allows researchers to assess the validity of the analytical approach and to compare our results against data generated using the same methods in their own or collaborating laboratories.
Our COA documentation includes recommended storage conditions derived from available stability data for each compound class. Where stability studies have been conducted, we summarize the key findings. Where relying on published literature, we cite the source. Researchers receive specific guidance on storage temperature, recommended container material, and reconstituted solution stability where this data is available.
Every COA we issue is publicly available through our documentation portal. Researchers can search by batch number, compound category, or release date. No account creation, purchase history, or approval process is required to access this documentation. We believe that access to quality documentation should not be contingent on commercial relationships — it is a basic resource for the research community.
Our operational standards are not a marketing document. They are the actual criteria that govern how we work. The following sections describe the specific standards we apply across the key dimensions of our operation.
We work exclusively with synthesis organizations that operate documented quality management systems. Our minimum requirement is a functioning quality management system that includes batch records, deviation management, change control, and stability assessment procedures. We verify these systems through documentation review and, for our primary partners, through periodic facility assessments.
Synthesis partner qualification is not a one-time event. We conduct annual re-evaluations of our synthesis partners that include review of any quality events, changes to facility or personnel, and updates to their analytical capabilities. Partners that experience significant quality events are placed on watch status, and any material from a partner on watch status undergoes enhanced incoming testing regardless of the partner's own quality release.
We do not source material from intermediary brokers. Every compound we supply has a documented direct relationship between PeakForce Labs and the synthesis organization that produced it. This allows us to make verified claims about synthesis conditions that would be impossible if material were sourced through undisclosed intermediary channels.
We require that all analytical methods used in our testing protocol be validated for the compound class being tested. Method validation is not a universal condition — an HPLC method developed and validated for one class of compounds may produce unreliable results for a structurally different compound. Our testing protocol specifies compound-class-appropriate methods for each analytical test in the panel.
We accept only results from accredited laboratories. For HPLC and mass spectrometry, we require ISO/IEC 17025 accreditation. For endotoxin testing, we require demonstrated proficiency in the LAL assay for the compound class in question. Accreditation certificates are reviewed during laboratory onboarding and verified annually.
Where new analytical technologies provide meaningful advantages over existing methods in our protocol, we evaluate them through a formal method transition process that includes side-by-side comparison on archived samples before any method change is implemented. We communicate method changes to our research customers through our documentation portal with appropriate notice.
Our documentation standard is built around one principle: every material fact about a batch must be traceable to a primary record. Summary documents, including our COA, are derivative — the underlying data files, laboratory reports, and batch records are the primary record, and they are maintained separately with access controls that prevent retroactive modification.
COA documents carry a version number and an issuance date. If additional information is added to a COA after initial issuance — for example, a supplementary stability data point — the document version is incremented and the amendment is logged. Original COA versions are never deleted or replaced, only superseded, and the version history of each document is available to any researcher who requests it.
We retain batch records and associated documentation for a minimum of ten years from the release date. For compounds where long-term stability data is being actively generated, documentation is retained for the duration of the stability program plus five years. Researchers who need documentation for work conducted using PeakForce compounds can request batch records for the entirety of this retention period.
Storage condition assignments are made based on the most conservative interpretation of available stability data for each compound class. Where peer-reviewed stability data supports a less stringent storage condition, we nonetheless default to the stricter requirement unless there is a specific operational reason to do otherwise. Our preference is to provide researchers with material that has been stored in conditions that preserve its integrity beyond what is technically required.
Our storage facility uses redundant temperature control systems with independent alarm monitoring. In the event of any temperature excursion, affected batches are quarantined and submitted for re-testing before any further distribution. We do not make case-by-case judgments about whether a particular excursion was "minor enough" to ignore — the re-testing protocol is applied uniformly.
We use IUPAC nomenclature and CAS Registry Numbers as the primary identification system for all compounds in our catalog. Common names and abbreviations are included as searchable secondary identifiers, but the primary record uses unambiguous systematic identification. This is particularly important for compound classes where common abbreviations are used inconsistently across different literature sources.
Our catalog descriptions are written to provide researchers with accurate information about the compound's chemical identity and known properties without making claims that extend beyond what the primary scientific literature supports. Where uncertainty exists in the literature, we note it. Where our documentation references specific publications, we provide full citation information. We do not write catalog descriptions that are designed to influence purchasing decisions rather than inform research planning.
These are not positioning statements. They are the operational differences that researchers have consistently identified when explaining why they continue to work with us.
Many suppliers publish COA documents that say "purity: passes specification" without telling researchers what the actual purity measurement was. We publish the numerical result — 99.3%, not "passes." This gives researchers the information they need to make their own assessment of whether a particular lot is suitable for their specific application.
We do not conduct our own analytical testing. Every purity claim, every identity confirmation, every endotoxin result on a PeakForce COA comes from an independent, accredited laboratory with no financial stake in the outcome of the testing. This structural independence is the only reliable basis for an objective quality claim.
When researchers contact us with questions about batch-to-batch variation, reconstitution behavior, or specific analytical results, they hear from someone who can engage with the chemistry. We do not route technical inquiries to customer service representatives whose role is to close support tickets. Technical questions receive substantive responses from people who understand the underlying science.
We maintain historical analytical data for every batch of each compound we have ever stocked. When a new batch arrives, its data is compared against the historical record to identify any meaningful variation. If a new batch shows a significant divergence from historical parameters — even if it meets absolute acceptance criteria — we investigate the cause before releasing the batch.
The lot number on every PeakForce shipment maps directly to a publicly accessible batch record and full COA. Researchers can include this lot number in their publications and grant other researchers the ability to access the same documentation. We have designed our lot numbering system specifically for this use case, and our documentation portal supports direct batch record lookup.
For compounds requiring cold-chain shipping, we use validated packaging configurations and include temperature monitoring indicators in each shipment. The temperature monitoring data is retained as part of the shipment record. If a package experiences a thermal excursion in transit, we have documented evidence of when it occurred and can assess whether a replacement shipment is warranted rather than making that determination based on verbal reports.
These are the questions we receive most frequently from researchers evaluating PeakForce as a supplier. We have answered them here as directly and completely as we can.
We answer technical questions directly. If you have questions about our compounds, documentation, or quality procedures, our team is available to help.